Peptides for PCOS: Emerging Research on Hormonal Balance and Metabolic Health

Peptides for PCOS: Emerging Research on Hormonal Balance and Metabolic Health

Polycystic Ovary Syndrome (PCOS) is a complex endocrine disorder affecting millions of women worldwide, characterized by hormonal imbalances, metabolic dysfunction, and reproductive issues. Emerging research suggests that various peptides hold significant promise in addressing the multifaceted challenges of PCOS by targeting key pathways involved in hormonal regulation, insulin sensitivity, and gut health. This article explores the current understanding and therapeutic potential of GLP-1 agonists, BPC-157, and kisspeptin in managing PCOS.

Key Takeaways

• GLP-1 Agonists (Semaglutide, Tirzepatide): Show significant potential in improving insulin resistance, promoting weight loss, and normalizing menstrual cycles in women with PCOS, particularly those with obesity. They work by enhancing glucose-dependent insulin secretion, reducing appetite, and exhibiting anti-inflammatory effects.
• BPC-157: While direct research on BPC-157 for PCOS is limited, its known regenerative and anti-inflammatory properties, especially concerning gut health, suggest a potential role in addressing gut dysbiosis and inflammation often associated with PCOS.
• Kisspeptin: Plays a crucial role in regulating LH pulsatility and the reproductive axis. Modulating kisspeptin signaling could offer a novel approach to restoring ovulatory function and hormonal balance in PCOS.
• Holistic Approach: Peptide therapies for PCOS are emerging as valuable tools that can complement lifestyle interventions and conventional treatments, offering targeted support for hormonal balance and metabolic health.

Understanding Polycystic Ovary Syndrome (PCOS)

PCOS is a heterogeneous disorder characterized by a combination of hyperandrogenism (excess male hormones), ovulatory dysfunction, and polycystic ovarian morphology [1]. Its exact etiology remains elusive, but it is understood to involve a complex interplay of genetic and environmental factors [2]. A significant driver of PCOS pathology is insulin resistance (IR), which affects a large percentage of women with the condition, even those who are not obese [3]. This IR leads to compensatory hyperinsulinemia, which in turn stimulates ovarian androgen production, creating a vicious cycle that exacerbates PCOS symptoms [4].

Beyond hormonal and metabolic dysregulation, chronic low-grade inflammation and gut dysbiosis are increasingly recognized as contributing factors to PCOS pathogenesis [5]. These interconnected issues highlight the need for comprehensive treatment strategies that address the underlying mechanisms of the syndrome.

GLP-1 Agonists: A Game Changer for Insulin Resistance and Weight Management

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications initially developed for type 2 diabetes, but their profound effects on weight loss and metabolic health have made them highly relevant for PCOS, especially in obese and insulin-resistant individuals [6]. GLP-1RAs, such as semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®), mimic the action of the natural incretin hormone GLP-1, which is released after food intake.

Mechanism of Action in PCOS

GLP-1RAs exert their beneficial effects through several mechanisms:

• Enhanced Glucose-Dependent Insulin Secretion: They stimulate the pancreas to release insulin only when blood glucose levels are high, reducing the risk of hypoglycemia [7].
• Reduced Glucagon Secretion: By suppressing glucagon release, GLP-1RAs help lower hepatic glucose production.
• Delayed Gastric Emptying: This slows down glucose absorption, leading to a more gradual rise in blood sugar after meals and promoting satiety [8].
• Appetite Suppression and Weight Loss: GLP-1RAs act on the brain's appetite centers, reducing hunger and food intake, which leads to significant and sustained weight loss [9]. This is particularly crucial for obese PCOS patients, as even a modest weight reduction (5-10%) can significantly improve hormonal and metabolic parameters [10].
• Anti-inflammatory Effects: Research indicates that GLP-1RAs possess anti-inflammatory properties, which can help mitigate the chronic low-grade inflammation often seen in PCOS [11].
• Improved Lipid Metabolism: They can positively influence lipid profiles by reducing triglycerides and LDL cholesterol levels [12].

Clinical Evidence for GLP-1 Agonists in PCOS

Studies have demonstrated the efficacy of GLP-1RAs in women with PCOS:

• A study on obese PCOS patients unresponsive to lifestyle modifications showed that treatment with low-dose semaglutide (0.5 mg once weekly) resulted in a mean body weight decrease of 7.6 kg and a mean BMI loss of 3.1 after three months. After six months, the mean body weight loss was 11.5 kg, and 80% of responsive patients experienced normalization of menstrual cycles [13].
• Another review highlighted that GLP-1RAs not only reduce body weight but also improve insulin resistance by increasing glucose transporter expression, decreasing inflammation, and modulating lipid metabolism. They can also improve fertility by influencing LH levels [6].

Comparison of GLP-1 Agonists for PCOS

BPC-157: Exploring its Role in Gut Health and Inflammation

Body Protection Compound-157 (BPC-157) is a synthetic peptide derived from human gastric juice, known for its regenerative and cytoprotective properties. While direct clinical trials on BPC-157 specifically for PCOS are lacking, its established benefits in gut health and inflammation suggest a potential indirect role in managing PCOS symptoms.

Relevance to PCOS

• Gut Dysbiosis: PCOS is often associated with alterations in gut microbiota composition, leading to increased gut permeability ( "leaky gut") and systemic inflammation [15]. This dysbiosis can exacerbate insulin resistance and hyperandrogenism.
• Inflammation: Chronic low-grade inflammation is a hallmark of PCOS, contributing to metabolic and reproductive dysfunction [16].

Potential Mechanisms of BPC-157

• Gut Healing: BPC-157 has been shown to promote the healing of the gastrointestinal tract, protecting against various noxious agents and maintaining gastric integrity [17]. It may help restore the gut barrier, reducing the translocation of inflammatory mediators into the bloodstream.
• Anti-inflammatory Properties: BPC-157 exhibits significant anti-inflammatory effects, potentially mitigating the systemic inflammation associated with PCOS [18].
• Angiogenesis and Tissue Repair: Its ability to stimulate angiogenesis (new blood vessel formation) and tissue repair could support overall metabolic health and recovery from inflammatory damage [19].

While BPC-157 is not a primary treatment for PCOS, its potential to address underlying gut issues and inflammation makes it an area of interest for holistic management strategies.

Kisspeptin: Modulating the Reproductive Axis

Kisspeptin is a neuropeptide encoded by the KISS1 gene, playing a pivotal role in the regulation of the hypothalamic-pituitary-gonadal (HPG) axis. It acts upstream of gonadotropin-releasing hormone (GnRH) neurons, stimulating the release of GnRH, which in turn triggers the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland [20].

The Role of Kisspeptin in PCOS

• LH Pulsatility: Women with PCOS often exhibit abnormal LH pulsatility, characterized by increased frequency and amplitude of LH pulses. This hypersecretion of LH drives ovarian theca cells to produce excess androgens, a core feature of PCOS [21].
• Kisspeptin Dysregulation: Research suggests that kisspeptin signaling may be dysregulated in PCOS. Some studies have found elevated kisspeptin levels in women with PCOS, potentially contributing to the hyperactive LH pulses [22].
• Therapeutic Potential: Modulating kisspeptin signaling presents a novel therapeutic target for PCOS. By dampening the overactive kisspeptin-GnRH-LH pathway, it may be possible to reduce androgen production and restore normal ovulatory function [23].

Emerging Research on Kisspeptin

• A study evaluating the temporal coupling between spontaneous kisspeptin and LH pulsatile releases in PCOS patients found that all patients demonstrated LH and kisspeptin pulsatile secretions, suggesting a complex interplay that warrants further investigation [24].
• Animal models of PCOS have shown that elevated kisspeptin and neurokinin B (NKB) gene expression likely drives increased LH pulsatility and androgen secretion [25].
• Clinical trials exploring kisspeptin antagonists or modulators are ongoing, aiming to determine their efficacy in normalizing LH levels and improving reproductive outcomes in women with PCOS [26].

What Women with PCOS Are Using

The landscape of PCOS management is evolving, and many women are exploring peptide therapies, often in conjunction with functional medicine approaches. While conventional treatments like oral contraceptives and metformin remain common, the use of peptides is gaining traction, particularly for addressing weight management and metabolic health.

• GLP-1 Agonists: Semaglutide and tirzepatide are increasingly prescribed off-label for weight loss in obese PCOS patients, with many reporting significant improvements in weight, insulin resistance, and menstrual regularity [27].
• BPC-157: Some women incorporate BPC-157 into their protocols to address gut health issues, inflammation, and overall well-being, often as part of a broader functional medicine strategy [28].
• Other Peptides: Peptides like CJC-1295/ipamorelin (for growth hormone stimulation and fat loss) and MOTS-c (for mitochondrial function and insulin sensitivity) are also being explored by some individuals seeking comprehensive metabolic support [29].

It is crucial to emphasize that the use of peptides for PCOS should be guided by a qualified healthcare professional, as individual responses can vary, and long-term safety data for some peptides are still emerging.

Frequently Asked Questions (FAQs)

1. Are GLP-1 agonists safe for women with PCOS? GLP-1 agonists like semaglutide and tirzepatide have shown significant promise in managing weight and insulin resistance in PCOS. However, they can cause gastrointestinal side effects (nausea, vomiting, diarrhea) and should be prescribed and monitored by a healthcare provider. They are generally not recommended during pregnancy.

2. Can BPC-157 cure PCOS? No, BPC-157 is not a cure for PCOS. It is a peptide known for its gut-healing and anti-inflammatory properties. While it may help address underlying issues like gut dysbiosis and inflammation often seen in PCOS, it should be considered a supportive therapy rather than a primary treatment.

3. How does kisspeptin affect fertility in PCOS? Kisspeptin regulates the release of hormones essential for ovulation (LH and FSH). In PCOS, kisspeptin signaling may be overactive, leading to excess LH and androgen production, which disrupts ovulation. Modulating kisspeptin could potentially help restore normal hormonal balance and improve fertility.

4. Do I need a prescription for peptide therapy for PCOS? Yes, most peptides used for therapeutic purposes, including GLP-1 agonists, require a prescription from a licensed healthcare provider. It is essential to obtain peptides from reputable pharmacies to ensure quality and safety.

5. Can I use peptides instead of lifestyle changes for PCOS? Peptides should not replace foundational lifestyle modifications. A healthy diet, regular exercise, and stress management remain the cornerstones of PCOS management. Peptides can be powerful adjuncts to these lifestyle changes, particularly for individuals who struggle to achieve results with lifestyle interventions alone.

6. What is the best peptide for weight loss in PCOS? Currently, GLP-1 agonists like semaglutide and the dual agonist tirzepatide have the most robust clinical evidence for significant weight loss and metabolic improvement in individuals with obesity and insulin resistance, which are common in PCOS.

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting any new treatment, including peptide therapy, especially if you have a medical condition like PCOS.

References

[1] Misso, M.; Costello, M.; Dokras, A.; Laven, J.; Moran, L.; Piltonen, T.; Norman, R. International Evidencebased for the Assessment and management of Polycystic Ovary Syndrome; Monash University: Melbourne, Australia, 2018; Volume 2. [2] Merkin, S.S.; Phy, J.L.; Sites, C.K.; Yang, D. Environmental Determinants of Polycystic Ovary Syndrome. Fertil. Steril. 2016, 106, 16–24. [3] Tosi, F.; Bonora, E.; Moghetti, P. Insulin Resistance in a Large Cohort of Women with Polycystic Ovary Syndrome: A Comparison between Euglycaemic-Hyperinsulinaemic Clamp and Surrogate Indexes. Hum. Reprod. 2017, 32, 2515–2521. [4] Diamanti-Kandarakis, E.; Dunaif, A. Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications. Endocr. Rev. 2012, 33, 981–1030. [5] Sathyapalan, T.; Atkin, S.L. Mediators of Inflammation in Polycystic Ovary Syndrome in Relation to Adiposity. Mediat. Inflamm. 2010, 2010, 758656. [6] Bednarz, K.; Kowalczyk, K.; Cwynar, M.; Czapla, D.; Czarkowski, W.; Kmita, D.; Nowak, A.; Madej, P. The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome. Int. J. Mol. Sci. 2022, 23(8), 4334. https://doi.org/10.3390/ijms23084334 [7] Meloni, A.R.; Deyoung, M.B.; Lowe, C.; Parkes, D.G. GLP-1 Receptor Activated Insulin Secretion from Pancreatic β-Cells: Mechanism and Glucose Dependence. Diabetes Obes. Metab. 2013, 15, 15–27. [8] Müller, T.D.; Finan, B.; Bloom, S.R.; D’Alessio, D.; Drucker, D.J.; Flatt, P.R.; Fritsche, A.; Gribble, F.; Grill, H.J.; Habener, J.F.; et al. Glucagon-like Peptide 1 (GLP-1). Mol. Metab. 2019, 30, 72–130. [9] Van Bloemendaal, L.; ten Kulve, J.S.; la Fleur, S.E.; Ijzerman, R.G.; Diamant, M. Effects of Glucagon-like Peptide 1 on Appetite and Body Weight: Focus on the CNS. J. Endocrinol. 2014, 221, T1–T16. [10] Legro, R. Obesity and PCOS: Implications for Diagnosis and Treatment. Semin. Reprod. Med. 2012, 30, 496–506. [11] Kanda, H.; Tateya, S.; Tamori, Y.; Kotani, K.; Hiasa, K.I.; Kitazawa, R.; Kitazawa, S.; Miyachi, H.; Maeda, S.; Egashira, K.; et al. MCP-1 Contributes to Macrophage Infiltration into Adipose Tissue, Insulin Resistance, and Hepatic Steatosis in Obesity. J. Clin. Investig. 2006, 116, 1494–1505. [12] Wong, C.; Lee, M.H.; Yaow, C.Y.L.; Chin, Y.H.; Goh, X.L.; Ng, C.H.; Lim, A.Y.L.; Muthiah, M.D.; Khoo, C.M. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis. Front. Endocrinol. 2021, 12, 332. [13] Carmina, E.; Longo, R.A. Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs. J. Clin. Med. 2023, 12(18), 5921. https://doi.org/10.3390/jcm12185921 [14] Anala, A.D.; Saifudeen, I.S.H.; Ibrahim, M.; Nanda, M.; et al. The potential utility of tirzepatide for the management of polycystic ovary syndrome. Journal of Clinical Medicine, 2023, 12(14), 4575. [15] Torres, P.J.; et al. Exposure to a Healthy Gut Microbiome Protects Against PCOS. PMC, 2019. [16] Rudnicka, E.; et al. Chronic Low Grade Inflammation in Pathogenesis of PCOS. PMC, 2021. [17] Sikiric, P.; et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Cytoprotection Solid Solid Tumor/Gastric Ulcer Healing. PMC, 2019. [18] McGuire, F.P.; et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. PMC, 2025. [19] Sikiric, P.; et al. Brain-gut Axis and Pentadecapeptide BPC 157. Curr Neuropharmacol. 2016 Nov;14(8):857–865. https://doi.org/10.2174/1570159X13666160502153022 [20] Tang, R.; Ding, X.; Zhu, J. Kisspeptin and polycystic ovary syndrome. Frontiers in endocrinology, 2019. [21] Emekci Ozay, O.; et al. Role of kisspeptin in polycystic ovary syndrome (PCOS). Gynecological Endocrinology, 2016. [22] Zarei, E.; et al. Kisspeptin levels in relation to sex hormone profile among PCOS patients. Irish Journal of Medical Science, 2022. [23] Aasif, A.; et al. The role of kisspeptin in the pathogenesis of a polycystic ovary syndrome. Endocrine Regulations, 2023. [24] Katulski, K.; et al. Kisspeptin and LH pulsatile temporal coupling in PCOS patients. Endocrine, 2018. [25] Podfigurna, A.; et al. Kisspeptin and LH pulsatility in patients with functional hypothalamic amenorrhea. Endocrine, 2020. [26] Salmeri, N.; et al. The kisspeptin system in and beyond reproduction: exploring intricate pathways and potential links between endometriosis and polycystic ovary syndrome. Reviews in endocrine and metabolic disorders, 2024. [27] Syren Medical. Best Peptides for PCOS & Insulin Resistance: Treatment Guide. 2025. [28] Holistic Health Code. How Functional Medicine Supports PCOS with Peptides. 2024. [29] Berman Sexual Health. PCOS Treatments Beyond Birth Control: Latest Options. 2025. ang, D. Environmental Determinants of Polycystic Ovary Syndrome. Fertil. Steril. 2016, 106, 16–24. [3] Tosi, F.; Bonora, E.; Moghetti, P. Insulin Resistance in a Large Cohort of Women with Polycystic Ovary Syndrome: A Comparison between Euglycaemic-Hyperinsulinaemic Clamp and Surrogate Indexes. Hum. Reprod. 2017, 32, 2515–2521. [4] Diamanti-Kandarakis, E.; Dunaif, A. Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications. Endocr. Rev. 2012, 33, 981–1030. [5] Sathyapalan, T.; Atkin, S.L. Mediators of Inflammation in Polycystic Ovary Syndrome in Relation to Adiposity. Mediat. Inflamm. 2010, 2010, 758656. [6] Bednarz, K.; Kowalczyk, K.; Cwynar, M.; Czapla, D.; Czarkowski, W.; Kmita, D.; Nowak, A.; Madej, P. The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome. Int. J. Mol. Sci. 2022, 23(8), 4334. https://doi.org/10.3390/ijms23084334 [7] Meloni, A.R.; Deyoung, M.B.; Lowe, C.; Parkes, D.G. GLP-1 Receptor Activated Insulin Secretion from Pancreatic β-Cells: Mechanism and Glucose Dependence. Diabetes Obes. Metab. 2013, 15, 15–27. [8] Müller, T.D.; Finan, B.; Bloom, S.R.; D’Alessio, D.; Drucker, D.J.; Flatt, P.R.; Fritsche, A.; Gribble, F.; Grill, H.J.; Habener, J.F.; et al. Glucagon-like Peptide 1 (GLP-1). Mol. Metab. 2019, 30, 72–130. [9] Van Bloemendaal, L.; ten Kulve, J.S.; la Fleur, S.E.; Ijzerman, R.G.; Diamant, M. Effects of Glucagon-like Peptide 1 on Appetite and Body Weight: Focus on the CNS. J. Endocrinol. 2014, 221, T1–T16. [10] Legro, R. Obesity and PCOS: Implications for Diagnosis and Treatment. Semin. Reprod. Med. 2012, 30, 496–506. [11] Kanda, H.; Tateya, S.; Tamori, Y.; Kotani, K.; Hiasa, K.I.; Kitazawa, R.; Kitazawa, S.; Miyachi, H.; Maeda, S.; Egashira, K.; et al. MCP-1 Contributes to Macrophage Infiltration into Adipose Tissue, Insulin Resistance, and Hepatic Steatosis in Obesity. J. Clin. Investig. 2006, 116, 1494–1505. [12] Wong, C.; Lee, M.H.; Yaow, C.Y.L.; Chin, Y.H.; Goh, X.L.; Ng, C.H.; Lim, A.Y.L.; Muthiah, M.D.; Khoo, C.M. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis. Front. Endocrinol. 2021, 12, 332. [13] Carmina, E.; Longo, R.A. Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs. J. Clin. Med. 2023, 12(18), 5921. https://doi.org/10.3390/jcm12185921 [14] Anala, A.D.; Saifudeen, I.S.H.; Ibrahim, M.; Nanda, M.; et al. The potential utility of tirzepatide for the management of polycystic ovary syndrome. Journal of Clinical Medicine, 2023, 12(14), 4575. [15] Torres, P.J.; et al. Exposure to a Healthy Gut Microbiome Protects Against PCOS. PMC, 2019. [16] Rudnicka, E.; et al. Chronic Low Grade Inflammation in Pathogenesis of PCOS. PMC, 2021. [17] Sikiric, P.; et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Cytoprotection Solid Solid Tumor/Gastric Ulcer Healing. PMC, 2019. [18] McGuire, F.P.; et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. PMC, 2025. [19] Sikiric, P.; et al. Brain-gut Axis and Pentadecapeptide BPC 157. Curr Neuropharmacol. 2016 Nov;14(8):857–865. https://doi.org/10.2174/1570159X13666160502153022 [20] Tang, R.; Ding, X.; Zhu, J. Kisspeptin and polycystic ovary syndrome. Frontiers in endocrinology, 2019. [21] Emekci Ozay, O.; et al. Role of kisspeptin in polycystic ovary syndrome (PCOS). Gynecological Endocrinology, 2016. [22] Zarei, E.; et al. Kisspeptin levels in relation to sex hormone profile among PCOS patients. Irish Journal of Medical Science, 2022. [23] Aasif, A.; et al. The role of kisspeptin in the pathogenesis of a polycystic ovary syndrome. Endocrine Regulations, 2023. [24] Katulski, K.; et al. Kisspeptin and LH pulsatile temporal coupling in PCOS patients. Endocrine, 2018. [25] Podfigurna, A.; et al. Kisspeptin and LH pulsatility in patients with functional hypothalamic amenorrhea. Endocrine, 2020. [26] Salmeri, N.; et al. The kisspeptin system in and beyond reproduction: exploring intricate pathways and potential links between endometriosis and polycystic ovary syndrome. Reviews in endocrine and metabolic disorders, 2024. [27] Syren Medical. Best Peptides for PCOS & Insulin Resistance: Treatment Guide. 2025. [28] Holistic Health Code. How Functional Medicine Supports PCOS with Peptides. 2024. [29] Berman Sexual Health. PCOS Treatments Beyond Birth Control: Latest Options. 2025. Piltonen, T.; Norman, R. International Evidencebased for the Assessment and management of Polycystic Ovary Syndrome; Monash University: Melbourne, Australia, 2018; Volume 2. [2] Merkin, S.S.; Phy, J.L.; Sites, C.K.; Yang, D. Environmental Determinants of Polycystic Ovary Syndrome. Fertil. Steril. 2016, 106, 16–24. [3] Tosi, F.; Bonora, E.; Moghetti, P. Insulin Resistance in a Large Cohort of Women with Polycystic Ovary Syndrome: A Comparison between Euglycaemic-Hyperinsulinaemic Clamp and Surrogate Indexes. Hum. Reprod. 2017, 32, 2515–2521. [4] Diamanti-Kandarakis, E.; Dunaif, A. Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications. Endocr. Rev. 2012, 33, 981–1030. [5] Sathyapalan, T.; Atkin, S.L. Mediators of Inflammation in Polycystic Ovary Syndrome in Relation to Adiposity. Mediat. Inflamm. 2010, 2010, 758656. [6] Bednarz, K.; Kowalczyk, K.; Cwynar, M.; Czapla, D.; Czarkowski, W.; Kmita, D.; Nowak, A.; Madej, P. The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome. Int. J. Mol. Sci. 2022, 23(8), 4334. https://doi.org/10.3390/ijms23084334 [7] Meloni, A.R.; Deyoung, M.B.; Lowe, C.; Parkes, D.G. GLP-1 Receptor Activated Insulin Secretion from Pancreatic β-Cells: Mechanism and Glucose Dependence. Diabetes Obes. Metab. 2013, 15, 15–27. [8] Müller, T.D.; Finan, B.; Bloom, S.R.; D’Alessio, D.; Drucker, D.J.; Flatt, P.R.; Fritsche, A.; Gribble, F.; Grill, H.J.; Habener, J.F.; et al. Glucagon-like Peptide 1 (GLP-1). Mol. Metab. 2019, 30, 72–130. [9] Van Bloemendaal, L.; ten Kulve, J.S.; la Fleur, S.E.; Ijzerman, R.G.; Diamant, M. Effects of Glucagon-like Peptide 1 on Appetite and Body Weight: Focus on the CNS. J. Endocrinol. 2014, 221, T1–T16. [10] Legro, R. Obesity and PCOS: Implications for Diagnosis and Treatment. Semin. Reprod. Med. 2012, 30, 496–506. [11] Kanda, H.; Tateya, S.; Tamori, Y.; Kotani, K.; Hiasa, K.I.; Kitazawa, R.; Kitazawa, S.; Miyachi, H.; Maeda, S.; Egashira, K.; et al. MCP-1 Contributes to Macrophage Infiltration into Adipose Tissue, Insulin Resistance, and Hepatic Steatosis in Obesity. J. Clin. Investig. 2006, 116, 1494–1505. [12] Wong, C.; Lee, M.H.; Yaow, C.Y.L.; Chin, Y.H.; Goh, X.L.; Ng, C.H.; Lim, A.Y.L.; Muthiah, M.D.; Khoo, C.M. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis. Front. Endocrinol. 2021, 12, 332. [13] Carmina, E.; Longo, R.A. Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs. J. Clin. Med. 2023, 12(18), 5921. https://doi.org/10.3390/jcm12185921 [14] Anala, A.D.; Saifudeen, I.S.H.; Ibrahim, M.; Nanda, M.; et al. The potential utility of tirzepatide for the management of polycystic ovary syndrome. Journal of Clinical Medicine, 2023, 12(14), 4575. [15] Torres, P.J.; et al. Exposure to a Healthy Gut Microbiome Protects Against PCOS. PMC, 2019. [16] Rudnicka, E.; et al. Chronic Low Grade Inflammation in Pathogenesis of PCOS. PMC, 2021. [17] Sikiric, P.; et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Cytoprotection Solid Solid Tumor/Gastric Ulcer Healing. PMC, 2019. [18] McGuire, F.P.; et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. PMC, 2025. [19] Sikiric, P.; et al. Brain-gut Axis and Pentadecapeptide BPC 157. Curr Neuropharmacol. 2016 Nov;14(8):857–865. https://doi.org/10.2174/1570159X13666160502153022 [20] Tang, R.; Ding, X.; Zhu, J. Kisspeptin and polycystic ovary syndrome. Frontiers in endocrinology, 2019. [21] Emekci Ozay, O.; et al. Role of kisspeptin in polycystic ovary syndrome (PCOS). Gynecological Endocrinology, 2016. [22] Zarei, E.; et al. Kisspeptin levels in relation to sex hormone profile among PCOS patients. Irish Journal of Medical Science, 2022. [23] Aasif, A.; et al. The role of kisspeptin in the pathogenesis of a polycystic ovary syndrome. Endocrine Regulations, 2023. [24] Katulski, K.; et al. Kisspeptin and LH pulsatile temporal coupling in PCOS patients. Endocrine, 2018. [25] Podfigurna, A.; et al. Kisspeptin and LH pulsatility in patients with functional hypothalamic amenorrhea. Endocrine, 2020. [26] Salmeri, N.; et al. The kisspeptin system in and beyond reproduction: exploring intricate pathways and potential links between endometriosis and polycystic ovary syndrome. Reviews in endocrine and metabolic disorders, 2024. [27] Syren Medical. Best Peptides for PCOS & Insulin Resistance: Treatment Guide. 2025. [28] Holistic Health Code. How Functional Medicine Supports PCOS with Peptides. 2024. [29] Berman Sexual Health. PCOS Treatments Beyond Birth Control: Latest Options. 2025.